Melanocortin System

Overview

The melanocortin system is one of the most functionally diverse peptide signaling networks in mammalian biology. Centered on a family of five melanocortin receptors (MC1R through MC5R) and their endogenous peptide ligands derived from the precursor protein pro-opiomelanocortin (POMC), this system regulates an remarkably broad range of physiological processes — from skin and hair pigmentation to appetite control, from adrenal steroidogenesis to sexual arousal.

In the peptide research community, the melanocortin system is of particular interest because several synthetic analogs targeting specific melanocortin receptors have been developed and studied extensively. Melanotan I and melanotan II, PT-141 (bremelanotide), and ACTH analogs all act through melanocortin receptors, making this system one of the most directly targeted by research peptides.

How It Works

POMC: The Precursor Molecule

Pro-opiomelanocortin (POMC) is a 241-amino acid precursor polypeptide expressed primarily in:

• Corticotroph cells of the anterior pituitary
• Neurons in the arcuate nucleus of the hypothalamus
• Keratinocytes in the skin
• Cells of the immune system

Through tissue-specific post-translational processing by prohormone convertases (PC1/3 and PC2), POMC is cleaved into multiple bioactive peptides:

• ACTH (adrenocorticotropic hormone) — Stimulates cortisol production from the adrenal cortex (via MC2R). Also the parent peptide from which alpha-MSH is derived.
• Alpha-MSH (α-melanocyte-stimulating hormone) — The primary endogenous melanocortin agonist. A 13-amino acid peptide that activates MC1R, MC3R, MC4R, and MC5R.
• Beta-MSH and Gamma-MSH — Additional melanocortin peptides with receptor subtype preferences.
• Beta-endorphin — An endogenous opioid peptide (from the C-terminal fragment of POMC); not a melanocortin ligand but co-released during POMC processing.

The Five Melanocortin Receptors

All melanocortin receptors are G-protein-coupled receptors (GPCRs) that signal primarily through Gs-protein coupling, activating adenylyl cyclase and increasing intracellular cAMP:

MC1R — Pigmentation

• Expression: Melanocytes (skin, hair follicles), immune cells
• Primary ligand: α-MSH
• Function: Stimulates eumelanin (dark pigment) production over pheomelanin (red/yellow pigment) via the cAMP-MITF-tyrosinase pathway. MC1R activation shifts the melanin ratio toward photoprotective eumelanin.
• Clinical relevance: MC1R polymorphisms are the primary genetic determinant of fair skin, red hair, and UV sensitivity. Loss-of-function variants increase melanoma risk.

MC2R — Adrenal Steroidogenesis

• Expression: Adrenal cortex (zona fasciculata and zona reticularis)
• Primary ligand: ACTH (the only melanocortin receptor that responds exclusively to ACTH, not α-MSH)
• Function: Stimulates cortisol, cortisone, and adrenal androgen production
• This receptor is the effector arm of the HPA axis at the adrenal level
• Requires the accessory protein MRAP (melanocortin-2 receptor accessory protein) for surface expression

MC3R — Energy Homeostasis

• Expression: Hypothalamus, limbic system, gut, placenta
• Primary ligands: α-MSH, γ-MSH
• Function: Modulates energy homeostasis, feeding efficiency, and fat partitioning. MC3R knockout mice develop a "metabolically obese" phenotype with increased adiposity despite normal food intake.
• Also expressed on immune cells, where it mediates anti-inflammatory effects

MC4R — Appetite and Sexual Function

• Expression: Widely expressed in the CNS — hypothalamus (paraventricular nucleus), brainstem, cortex, spinal cord
• Primary ligand: α-MSH (agonist); agouti-related peptide (AgRP, endogenous antagonist)
• Function: Central regulator of appetite suppression and energy expenditure. MC4R activation reduces food intake. MC4R also mediates central melanocortin effects on erectile function and sexual behavior.
• MC4R is the most common monogenic cause of human obesity — loss-of-function MC4R mutations account for approximately 5-6% of severe early-onset obesity cases.

MC5R — Exocrine Function

• Expression: Exocrine glands (sebaceous, lacrimal, preputial), adrenal gland, adipose tissue, immune cells
• Primary ligand: α-MSH
• Function: Regulates sebaceous lipid production and exocrine gland secretion. MC5R knockout mice show severely reduced sebaceous lipid production. Also implicated in immune regulation.

Endogenous Antagonists

The melanocortin system is unique among GPCR systems in having endogenous antagonists:

• Agouti signaling protein (ASIP) — Antagonist at MC1R (and weakly MC4R). Expressed in skin, where it causes pheomelanin production, creating the agouti hair banding pattern seen in many mammals.
• Agouti-related peptide (AgRP) — Potent inverse agonist/antagonist at MC3R and MC4R. Expressed in NPY/AgRP neurons in the arcuate nucleus. AgRP opposes α-MSH to stimulate appetite — the POMC/α-MSH vs. NPY/AgRP neuron balance is a central mechanism of hypothalamic appetite regulation.

Key Components

Role in Peptide Research

Melanotan I (Afamelanotide)

A linear analog of α-MSH with enhanced stability (substitutions at positions 4 and 7 of the α-MSH sequence). Selective for MC1R. Stimulates eumelanin production, producing skin darkening (tanning) without UV exposure. FDA-approved as Scenesse for erythropoietic protoporphyria (EPP), a rare photosensitivity disorder.

Melanotan II

A cyclic heptapeptide analog of α-MSH. Unlike Melanotan I, it is a non-selective melanocortin agonist with significant activity at MC1R, MC3R, MC4R, and MC5R. This broad receptor profile produces multiple effects: skin tanning (MC1R), appetite suppression (MC4R), and pro-erectile/pro-sexual effects (MC4R). Melanotan II is not approved for clinical use and remains a research compound.

PT-141 (Bremelanotide)

A metabolite of Melanotan II, PT-141 is an MC4R agonist (with some MC1R activity). FDA-approved as Vyleesi for hypoactive sexual desire disorder (HSDD) in premenopausal women. It is the first melanocortin-based drug approved specifically for sexual dysfunction, validating the role of MC4R in central sexual arousal pathways.

Setmelanotide

An MC4R-selective agonist approved (as Imcivree) for obesity caused by POMC, PCSK1, or LEPR deficiency — rare genetic conditions where the melanocortin appetite-suppression pathway is impaired. Demonstrates the therapeutic potential of targeted melanocortin receptor modulation.

KPV

A C-terminal tripeptide fragment of α-MSH (Lys-Pro-Val) that retains anti-inflammatory properties without significant melanogenic activity. KPV has been studied for anti-inflammatory effects in colitis models, acting partly through inhibition of the NF-kB pathway.

Clinical Significance

• Obesity — MC4R is validated as a critical target for appetite regulation. Both genetic loss-of-function (causing obesity) and pharmacological activation (causing appetite suppression) confirm its central role.
• Pigmentary disorders — MC1R modulation has therapeutic applications in photoprotection and vitiligo.
• Sexual dysfunction — MC4R agonism (PT-141/bremelanotide) represents a novel mechanism for treating HSDD, distinct from hormonal or PDE5-inhibitor approaches.
• Inflammatory disease — Melanocortin peptides, particularly through MC1R and MC3R, exert potent anti-inflammatory effects that are being explored for conditions including arthritis and inflammatory bowel disease.
• Adrenal insufficiency — MC2R is the effector of ACTH in the HPA axis; disruption causes adrenal insufficiency.

Related Topics

• HPA Axis — ACTH/MC2R mediates adrenal cortisol production
• HPG Axis — MC4R modulates sexual function centrally
• NF-kB Pathway — Melanocortin anti-inflammatory effects partly via NF-kB inhibition
• Growth Hormone Axis — POMC neurons interact with GH regulation in the hypothalamus